March 2020

Contents

Editorial

• HTB 27 March 2020: CoV-2 and COVID-2019 special edition

• HTB 12 March 2020 now online

• HTB survey 2020 – please help with feedback

Special reports

• Fit for purpose: antiretroviral treatment optimisation March 2020

• HIV pipeline 2020: new drugs in development – March 2020

Conference reports

• Conference on Retroviruses and Opportunistic Infections (CROI 2020)

• CROI 2020: Special session on COVID-19

• Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally

• Long-acting cabotegravir and rilpivirine injections support two-monthly dosing

• Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing

• First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance

• Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial

• Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women

• London patient is second person to be cured of HIV from allogeneic stem-cell transplant

• The London Patient tells his story as second person cured of HIV

Treatment strategies

• Early drugs being studied for COVID-19

Treatment access

• Dolutegravir/lamivudine FDC recommended by NHS England

PK and drug interactions

• Drug-drug interactions and COVID-19

HIV prevention and transmission

• Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

COVID-19: pathogenesis

• Clinical outcomes of adult inpatients with COVID-19

• Clinical characteristics of COVID-19 in China

• COVID-19 is associated with significant drops in CD4 count

• CoV-2 viral load in throat saliva samples correlates with clinical outcomes from COVID-19

COVID-19: guidelines

• US interim guidelines on COVID-19 and HIV

• BHIVA statements on HIV and COVID-19

• Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition)

• Children’s HIV Association (CHIVA) statement on COVID-19

• WHO guidance on severe acute respiratory infection when COVID-19 is suspected

• NICE updates rapid COVID-19 guideline on critical care 

• US CDC clinical guidance for management of patients with confirmed COVID-19

• French guidelines for protection of cancer patients against COVID-19

• Guidelines for managing COVID-19 from the Survive Sepsis Campaign

• IDSA resource center on COVID-19

COVID-19: transmission & prevention

• Median estimated incubation period of COVID-19 is five days – but can be two weeks

• Selected epidemiology links and papers for COVID-19

• Rapid and point of care testing for SARS-CoV-2

• Peer-review articles on COVID-19 and pregnancy

• Sex, HIV and STIs during COVID-19 pandemic

COVID-19: research studies

• Ongoing and planned studies for COVID-19

• NEAT ID develop COVID-19 and HIV coinfection data dashboard

• Open access publications on COVID-19 include Lancet, Nature, NEJM, JAMA, JID, CID and others

• Open access publishing on US PubMed Central

• Selected articles by UCSF: download 60 papers

COVID-19: on the web

• Online information for people living with HIV

• Online talks about COVID-19

PDFs

• 27 March 2020 vol 21 no 4

• 12 March 2020 vol 21 no 3